Does stem cell therapy help with COPD?
Stem cell therapy for COPD is in early clinical development. The rationale is that MSCs can reduce pulmonary inflammation, modulate immune responses, and potentially support lung tissue repair. Phase 1 and 2 trials have shown the treatment is safe and some patients report improved exercise capacity (6-minute walk test) and quality of life. However, no large randomized controlled trial has confirmed efficacy, and the treatment does not reverse established lung damage (emphysema). It is most commonly pursued by patients who have not responded adequately to standard COPD management.
What COPD patients are most likely to benefit?
Based on available evidence, patients with moderate COPD (GOLD Stage 2–3) who still have meaningful lung function appear to be better candidates than those with very severe disease (GOLD Stage 4). Patients with a significant inflammatory component (chronic bronchitis type) may respond better than those with predominantly emphysematous disease. A thorough pulmonary evaluation including spirometry and CT scan should precede any treatment decision.
